Observational multicentric national longitudinal study evaluating Ibrance (palbociclib) in a real life setting conditions in patients 70 years old and older presenting a locally advanced or metastatic HR+/HER2- breast cancer (PalomAGE)

07/03/2018
16/12/2025
EU PAS number:
EUPAS23012
Study
Finalised
Documents
Study protocol
Study results
Study report
Other information
Publications
ENCePP Seal
Composition of steering group and observers
English (18.87 KB - PDF) View document